[Combine low-dose heparin with prostaglandin E1 and Dextran 40 to prevent and treat hepatic veno-occlusive disease after hematopoietic stem cell transplantation].
Li
Qiu-ping
QP
Zhu
Wei-guo
WG
Yin
Xiao-juan
XJ
Feng
Zhi-chun
ZC
D000293:Adolescent; D000328:Adult; D000527:Alprostadil / Q000494:pharmacology*; D000925:Anticoagulants / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D003911:Dextrans / Q000494:pharmacology*; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006493:Heparin / Q000494:pharmacology*; D006504:Hepatic Veno-Occlusive Disease / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D016896:Treatment Outcome
D000925:Anticoagulants; D003911:Dextrans; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D000527:Alprostadil